Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis
Purpose
The primary goal of the trial is to determine if the experimental arms (rivaroxaban or ticagrelor or both) are superior to the clopidogrel arm for lowering the 1-year rate of ischemic stroke, intracerebral hemorrhage, or vascular death.
Conditions
- Intracranial Arteriosclerosis
- Stroke
Eligibility
- Eligible Ages
- Over 30 Years
- Eligible Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Acute focal symptoms or signs of any duration associated with imaging, pathological, or other objective evidence of arterial infarction OR clinical evidence of cerebral, spinal cord, or retinal focal arterial ischemic injury based on symptoms persisting greater than or equal to 24 hours that occurred within 30 days prior to randomization - Index stroke is attributed to 70-99% stenosis (or flow gap on MRA) of a major intracranial artery (carotid artery, middle cerebral artery (M1 or M2), vertebral artery (V4), basilar artery, posterior cerebral artery (P1), or anterior cerebral artery (A1)) documented by CTA, MRA, or catheter angiography - Modified Rankin Scale score of ≤ 4, at time of consent - Ability to swallow pills - At least 30 years of age, inclusive, at time of consent - Subjects 30-49 years of age are required to meet at least ONE of the following additional criteria below to qualify for the study: 1. diabetes treated with insulin for at least 15 years 2. at least 2 of the following atherosclerotic risk factors: hypertension (BP > 140/90 or on antihypertensive therapy); dyslipidemia (LDL > 130 mg /dl or HDL < 40 mg/dl or fasting triglycerides > 150 mg/dl or on lipid lowering therapy); smoking; non-insulin dependent diabetes or insulin dependent diabetes of less than 15 years duration; any of the following vascular events occurring in a parent or sibling who was < 55 years of age for men or < 65 years of age for women at the time of the event: myocardial infarction, coronary artery bypass, coronary angioplasty or stenting, stroke, carotid endarterectomy or stenting, peripheral vascular surgery for atherosclerotic disease 3. personal history of any of the following: myocardial infarction, coronary artery bypass, coronary angioplasty or stenting, carotid endarterectomy or stenting, or peripheral vascular surgery for atherosclerotic disease 4. any stenosis of an extracranial carotid or vertebral artery, another intracranial artery, subclavian artery, coronary artery, iliac or femoral artery, other lower or upper extremity artery, mesenteric artery, or renal artery that was documented by non-invasive vascular imaging or catheter angiography and is considered atherosclerotic 5. aortic arch atheroma documented by non-invasive vascular imaging or catheter angiography 6. any aortic aneurysm documented by non-invasive vascular imaging or catheter angiography that is considered atherosclerotic - Negative pregnancy test in a female who has had any menses in the last 18 months and has not had surgery that would make her unable to become pregnant - Subject is willing and able to return for all follow-up evaluations required by the protocol - Subject is available by phone - Subject understands the purpose and requirements of the study and can make him/herself understood - Subject has provided informed consent (use of a LAR is not permitted)
Exclusion Criteria
- Previous treatment of qualifying intracranial artery with a stent, angioplasty, or other mechanical device, including mechanical thrombectomy for the qualifying stroke, or plan to perform one of these procedures - Plan to perform concomitant endarterectomy, angioplasty or stenting of an extracranial vessel tandem to the symptomatic intracranial stenosis - Intracranial tumor (except meningioma) or any intracranial vascular malformation - Thrombolytic therapy within 24 hours prior to randomization - Progressive neurological signs within 24 hours prior to randomization - History of spontaneous non-traumatic intracranial hemorrhage (parenchymal, subarachnoid, subdural, epidural) - Intracranial arterial stenosis due to: arterial dissection; MoyaMoya disease; any known vasculitic disease; herpes zoster, varicella zoster or other viral vasculopathy; neurosyphilis; any other intracranial infection; any intracranial stenosis associated with CSF pleocytosis; radiation induced vasculopathy; fibromuscular dysplasia; sickle cell disease; neurofibromatosis; benign angiopathy of central nervous system; postpartum angiopathy; suspected vasospastic process; reversible cerebral vasoconstriction syndrome (RCVS); suspected recanalized embolus - Presence of any of the following unequivocal cardiac sources of embolism: chronic or paroxysmal atrial fibrillation, mitral stenosis, mechanical valve, endocarditis, intracardiac clot or vegetation, myocardial infarction within three months, left atrial spontaneous echo contrast - Known allergy or contraindication to aspirin, rivaroxaban, clopidogrel, or ticagrelor - Uncontrolled severe hypertension (systolic pressure > 180 mm Hg or diastolic pressure > 115 mm Hg), active peptic ulcer disease, major systemic hemorrhage within 30 days prior to randomization, active bleed or bleeding diathesis, platelets < 100,000, hematocrit < 30, INR > 1.5, clotting factor abnormality that increases the risk of bleeding, current alcohol or substance abuse, severe liver impairment (AST or ALT > 3 x normal, cirrhosis), or CrCl < 15 mL/min or on dialysis - Major surgery (including stenting of any vessel; open femoral, aortic, or carotid surgery; or cardiac surgery) within previous 30 days prior to randomization or planned in the next 90 days after randomization - Any condition other than intracranial arterial stenosis that requires the subject to take any antithrombotic medication other than aspirin (NOTE: exceptions allowed for subcutaneous heparin or enoxaparin for deep vein thrombosis (DVT) prophylaxis) - Dementia or psychiatric problem that prevents the subject from following an outpatient program reliably - Co-morbid conditions that may limit survival to less than 12 months - Pregnancy or of childbearing potential and unwilling to use contraception for the duration of this study, or currently breastfeeding - Current or anticipated concomitant oral or intravenous therapy with strong CYP3A4 inhibitors or CYP3A4 substrates that cannot be stopped for the course of this study - Enrollment in another study that would conflict with the current study
Study Design
- Phase
- Phase 3
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel Assignment
- Primary Purpose
- Prevention
- Masking
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Masking Description
- 1:1:1 treatment allocation
Arm Groups
Arm | Description | Assigned Intervention |
---|---|---|
Experimental Experimental Arm: Ticagrelor and Aspirin |
Ticagrelor (180mg loading dose, then 90mg twice daily) and aspirin (81mg daily) |
|
Active Comparator Standard of Care Arm: Clopidogrel and Aspirin |
Clopidogrel (600mg loading dose, then 75mg once daily) and aspirin (81mg daily) |
|
Experimental Experimental Arm: Rivaroxaban and Aspirin |
Rivaroxaban (2.5mg twice daily) and aspirin (81mg daily) |
|
Recruiting Locations
Birmingham 4049979, Alabama 4829764 35233
Mobile 4076598, Alabama 4829764 36604
Phoenix 5308655, Arizona 5551752 85013
Carmichael 5334336, California 5332921 95608
Chula Vista 5336899, California 5332921 91910
Fontana 5349755, California 5332921 92335
Long Beach 5367929, California 5332921 90806
Los Alamitos 5368304, California 5332921 90720
Los Angeles 5368361, California 5332921 90027
Sacramento 5389489, California 5332921 95817
Torrance 5403022, California 5332921 90503
Aurora 5412347, Colorado 5417618 80045
Grand Junction 5423573, Colorado 5417618 81501
Hartford 4835797, Connecticut 4831725 06102
New Haven 4839366, Connecticut 4831725 06520
Washington D.C. 4140963, District of Columbia 4138106 20010
Clearwater 4151316, Florida 4155751 33756
Fort Lauderdale 4155966, Florida 4155751 33316
Gainesville 4156404, Florida 4155751 32608
Jacksonville 4160021, Florida 4155751 32207
Miami 4164138, Florida 4155751 33136
Port Saint Lucie 4169171, Florida 4155751 34987
Atlanta 4180439, Georgia 4197000 30303
Atlanta 4180439, Georgia 4197000 30303
Carbondale 4235193, Illinois 4896861 62901
Chicago 4887398, Illinois 4896861 60612
Chicago 4887398, Illinois 4896861 60612
Chicago 4887398, Illinois 4896861 60637
Evanston 4891382, Illinois 4896861 60201
Rockford 4907959, Illinois 4896861 61114
Kansas City 4273837, Kansas 4273857 66160
Lexington 4297983, Kentucky 6254925 40503
New Orleans 4335045, Louisiana 4331987 70121
Boston 4930956, Massachusetts 6254926 02114
Boston 4930956, Massachusetts 6254926 02115
Boston 4930956, Massachusetts 6254926 02118
Boston 4930956, Massachusetts 6254926 02215
Flint 4992982, Michigan 5001836 48532
Mount Clemens 5002656, Michigan 5001836 48043
Wyoming 5015618, Michigan 5001836 49519
Edina 5025264, Minnesota 5037779 55414
Minneapolis 5037649, Minnesota 5037779 55407
Minneapolis 5037649, Minnesota 5037779 55415
Jackson 4431410, Mississippi 4436296 39216
Columbia 4381982, Missouri 4398678 65212
St Louis 4407066, Missouri 4398678 62269
Omaha 5074472, Nebraska 5073708 68198
Camden 4501018, New Jersey 5101760 08103
Neptune City 5101687, New Jersey 5101760 07753
Albuquerque 5454711, New Mexico 5481136 87106
Brooklyn 5110302, New York 5128638 11203
Brooklyn 5110302, New York 5128638 11203
Brooklyn 5110302, New York 5128638 11220
Buffalo 5110629, New York 5128638 14202
Lake Success 5123853, New York 5128638 11042
New York 5128581, New York 5128638 10021
New York 5128581, New York 5128638 10029
New York 5128581, New York 5128638 10032
Charlotte 4460243, North Carolina 4482348 28207
Durham 4464368, North Carolina 4482348 27710
Greensboro 4469146, North Carolina 4482348 27405
Greenville 4469160, North Carolina 4482348 27834
Winston-Salem 4499612, North Carolina 4482348 27157
Akron 5145476, Ohio 5165418 44307
Cincinnati 4508722, Ohio 5165418 45220
Cincinnati 4508722, Ohio 5165418 45267
Cleveland 5150529, Ohio 5165418 44106
Columbus 4509177, Ohio 5165418 43210
Toledo 5174035, Ohio 5165418 43606
Toledo 5174035, Ohio 5165418 43608
Oklahoma City 4544349, Oklahoma 4544379 73104
Abington 5177773, Pennsylvania 6254927 19001
Philadelphia 4560349, Pennsylvania 6254927 19104
Philadelphia 4560349, Pennsylvania 6254927 19107
Philadelphia 4560349, Pennsylvania 6254927 19140
Pittsburgh 5206379, Pennsylvania 6254927 15213
Providence 5224151, Rhode Island 5224323 02903
Charleston 4574324, South Carolina 4597040 29425
Columbia 4575352, South Carolina 4597040 29203
Greenville 4580543, South Carolina 4597040 29605
Memphis 4641239, Tennessee 4662168 38104
Galveston 4692883, Texas 4736286 77555
Houston 4699066, Texas 4736286 77030
Houston 4699066, Texas 4736286 77030
Lubbock 5525577, Texas 4736286 79410
Plano 4719457, Texas 4736286 75075
San Antonio 4726206, Texas 4736286 78229
Charlottesville 4752031, Virginia 6254928 22903
Falls Church 4758390, Virginia 6254928 22042
Roanoke 4782167, Virginia 6254928 24011
Seattle 5809844, Washington 5815135 98122
More Details
- NCT ID
- NCT05047172
- Status
- Recruiting
- Sponsor
- University of Florida
Detailed Description
The proposed study is relevant to public health because narrowing of brain arteries is one of the most common causes of stroke worldwide. Compelling evidence suggests novel antithrombotic medications could reduce the rate of stroke in patients with narrowed brain arteries. The proposed study will directly compare novel antithrombotic medications to standard care antiplatelet medications for preventing stroke and death from vascular causes in patients with narrowed brain arteries.